NCT02302157: A reported trial by Lineage Cell Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02302157 |
|---|---|
| Title | A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2015 |
| Completion date | Dec. 31, 2018 |
| Required reporting date | Dec. 31, 2021, midnight |
| Actual reporting date | Dec. 15, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |